Your shopping cart is currently empty

Brinzolamide (AL-4862) is a Carbonic Anhydrase Inhibitor. Its mechanism of action involves inhibiting the enzyme Carbonic Anhydrase.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $30 | In Stock | In Stock | |
| 25 mg | $58 | In Stock | In Stock | |
| 50 mg | $89 | In Stock | In Stock | |
| 100 mg | $130 | In Stock | In Stock | |
| 500 mg | $272 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock | In Stock |
| Description | Brinzolamide (AL-4862) is a Carbonic Anhydrase Inhibitor. Its mechanism of action involves inhibiting the enzyme Carbonic Anhydrase. |
| Targets&IC50 | CA II:3.19 nM |
| In vitro | A 0.6 mg dose of Brinzolamide ophthalmic suspension reduces intraocular pressure in a dose-dependent manner in cynomolgus monkeys post-laser glaucoma surgery. Similarly, it lowers intraocular pressure in Dutch belted rabbits. Dosages of 1 mg/kg, 10 mg/kg, and 30 mg/kg of Brinzolamide prolong the sleep time induced by barbital in male CD-1 mice by 57%, 15%, and 35%, respectively. Less than 3% of Brinzolamide significantly increases both the percentage reduction and the mean decrease in intraocular pressure among patients with primary open-angle glaucoma or ocular hypertension compared to a placebo group. Additionally, a 2% Brinzolamide solution enhances optic nerve head blood flow and reduces intraocular pressure in resting Dutch belted rabbits. |
| Synonyms | AL-4862 |
| Molecular Weight | 383.51 |
| Formula | C12H21N3O5S3 |
| Cas No. | 138890-62-7 |
| Smiles | O=S1(=O)C2=C([C@@H](NCC)CN1CCCOC)C=C(S(N)(=O)=O)S2 |
| Relative Density. | 1.50 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 60 mg/mL (156.45 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.21 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.